Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

• 主要な著者: Rasoul Akbari (著者), Tahereh Behdarvand (著者), Reza Afarin (著者), Hamid Yaghooti (著者), Mohammad Taha Jalali (著者), Narges Mohammadtaghvaei (著者)
• フォーマット: 図書
• 出版事項: BMC, 2021-10-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have become significant global health concerns. In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARα/γ agonist, fenofibrate, a PPAR-α agonist, and pioglitazone, a...